

More detail on each of these medications can be found in our **medications factsheets** that summarise the key information, including potential side effects, to provide you with background information that you can then discuss with your healthcare providers.

| | Disease Modifying Therapies (DMTs) | | | | | | | | | | | | Symptomatic Therapies | | | |
|---|------------------------------------|---|--|-------------------------|---|-------------------------|--|---|---------------------------------------|---|---|--|--|---|-------------------------------------|--|
| | oral tablet | | | | injection | | | | | infusion | | | | | | |
| Brand name | Aubagio® note 1 | Gilenya® | MAVENCLAD® | Mayzent® | Tecfidera® | Avonex® | Betaferon® | Copaxone® | Plegridy® | Rebif® | Lemtrada® | Ocrevus® | Tysabri® | Botox® | Fampyra® | Sativex® |
| Generic name | teriflunomide | fingolimod | cladribine tablets | siponimod | dimethyl fumarate | interferon b-1a | interferon b-1b | glatiramer acetate | interferon b-1a (pegylated) | interferon b-1a | alemtuzumab | ocrelizumab | natalizumab | botulinum toxin type A | fampridine | nabiximols |
| Manufacturer | Sanofi Genzyme | Novartis Australia | Merck | Novartis Australia | Biogen | Biogen | Bayer Australia | Teva | Biogen | Merck Serono | Sanofi Genzyme | Roche | Biogen | Allergan | Biogen | Emerge Health Pty Ltd |
| Indications (forms of MS that the treatment is used for) | Relapsing remitting MS (RRMS) | Relapsing forms of MS (RRMS and relapsing SPMS) | RRMS | SPMS | RRMS | RRMS | Single clinical event indicating high risk of MS, RRMS, SPMS | Single clinical event indicating high risk of MS & RRMS | RRMS | Single clinical event indicating high risk of MS & RRMS | RRMS | RRMS & Primary Progressive MS (PPMS) | RRMS (Use in paediatric patients with RRMS approved by Gov't 28/10/19 effective 1/11/19) | Any form of MS; for treatment of urinary incontinence | Any form of MS; to improve walking | Muscle stiffness (spasticity) |
| Route | oral tablet | oral capsule | oral tablet | oral tablet | oral capsule | intramuscular injection | subcutaneous injection | subcutaneous injection | subcutaneous injection | subcutaneous injection | intravenous infusion | intravenous infusion | intravenous infusion | intramuscular injection | oral tablet | oromucosal (mouth) spray |
| Dosage and Frequency | one 14 mg tablet per day | Adults and paediatric patients over 40 kg: one 0.5 mg capsule per day Paediatric patients 40kg and under: 0.25mg capsule per day | Two treatment courses over two years; each treatment course consists of two weeks. | once daily | one 120mg capsule twice daily, increasing to 240g twice daily | once per week | every two days | 40 mg, three times per week OR 20 mg daily (20 mg dose not available after 1-7-19) | every two weeks | three times per week | two treatment courses, 1 year apart | 6 monthly; first treatment is split into 2 doses a fortnight apart | every 28 days | single treatment | Two tablets per day, 12 hours apart | A number of sprays per day depending on individual circumstances |
| Preparation | film coated oral tablet | gel capsules | uncoated tablets | film coated oral tablet | capsule | pre-filled syringe | pre-filled syringe | pre-filled syringe | single-use, pre-filled injection pens | pre-filled cartridge | prepared by pharmacy or clinic staff | prepared by pharmacy or clinic staff | prepared by pharmacy or clinic staff | multiple injections by doctor during one visit | film coated oral tablet | 10mL glass spray container and a pump |
| Storage | room temperature, below 30°C | room temperature, below 30°C | room temperature, below 25°C | refrigerate 2-8°C | room temperature, below 30°C | refrigerate 2-8°C | room temperature, below 25°C | refrigerate 2-8°C | refrigerate 2-8°C | refrigerate 2-8°C | stored in the pharmacy or clinic at 2-8°C | stored in the pharmacy or clinic at 2-8°C | stored in the pharmacy or clinic at 2-8°C | doctor will arrange storage | room temperature, below 25°C | refrigerate 2-8°C |
| Available on PBS | Yes | 0.5mg dosage capsules - yes 0.25mg capsules - yes from 1 Nov 2019 | Yes (from 1 Jan 2019) | No | Yes | Yes | Yes, RRMS only, not for single clinical event | Yes, RRMS only, not for single clinical event. 20 mg dose deleted from PBS from 1-7-19 | Yes | Yes, RRMS only, not for single clinical event | Yes | RRMS Yes PPMS No | Yes (from 1/11/19 for paediatric patients) | Yes | No | No |

Note 1: A generic version of teriflunomide is now available, please visit: <https://www.msaustralia.org.au/about-ms/medications-treatments>